Deutsche Bank AG Invests $68.87 Million in Moderna, Inc. $MRNA

Deutsche Bank AG bought a new stake in Moderna, Inc. (NASDAQ:MRNA) during the second quarter, HoldingsChannel reports. The fund bought 983,450 shares of the company’s stock, valued at approximately $68,871,000.

Other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. raised its holdings in shares of Moderna by 1.0% during the fourth quarter. Vanguard Group Inc. now owns 41,584,782 shares of the company’s stock worth $1,226,335,000 after purchasing an additional 399,487 shares during the last quarter. Capital World Investors acquired a new position in Moderna during the fourth quarter valued at $378,299,000. Invesco Ltd. boosted its holdings in Moderna by 15.7% in the third quarter. Invesco Ltd. now owns 8,216,163 shares of the company’s stock valued at $212,223,000 after purchasing an additional 1,115,131 shares during the last quarter. Theleme Partners LLP boosted its holdings in Moderna by 8.6% in the second quarter. Theleme Partners LLP now owns 7,868,810 shares of the company’s stock valued at $217,100,000 after purchasing an additional 626,420 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Moderna by 7.2% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,621,558 shares of the company’s stock worth $136,290,000 after purchasing an additional 309,126 shares during the period. 75.33% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Moderna

In other Moderna news, insider Shannon Thyme Klinger sold 3,471 shares of the firm’s stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $50.00, for a total value of $173,550.00. Following the completion of the sale, the insider directly owned 67,468 shares of the company’s stock, valued at $3,373,400. This trade represents a 4.89% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total value of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This represents a 3.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 10.80% of the stock is currently owned by company insiders.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Moderna in a research note on Friday, June 12th. Wolfe Research reaffirmed an “underperform” rating and issued a $25.00 price objective on shares of Moderna in a report on Monday, July 20th. William Blair raised shares of Moderna from a “market perform” rating to an “outperform” rating in a research note on Wednesday. Royal Bank Of Canada restated a “sector perform” rating and set a $130.00 target price on shares of Moderna in a research report on Wednesday. Finally, Morgan Stanley raised their price objective on Moderna from $39.00 to $89.00 and gave the company an “equal weight” rating in a report on Thursday. Four analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $66.25.

Key Moderna News

Here are the key news stories impacting Moderna this week:

• Positive Sentiment: Phase 3 melanoma success validates Moderna’s mRNA platform. Moderna and Merck said their personalized cancer vaccine, intismeran autogene, combined with Keytruda, met both recurrence-free-survival and distant-metastasis-free-survival endpoints in high-risk, fully resected Stage IIB-IV melanoma patients. The result is described as the first positive late-stage trial for a personalized mRNA cancer vaccine and could support regulatory filings as early as 2027. Merck and Moderna Phase 3 trial announcement
• Positive Sentiment: Investors see potential beyond COVID-19 vaccines. Analysts believe a successful personalized oncology product could establish a major new revenue stream and raise the value of Moderna’s broader cancer pipeline, including programs targeting lung, kidney and bladder cancers. Jefferies estimated potential global peak sales of approximately $54 billion and raised its price target to $170, while other estimates were more conservative. Moderna oncology platform draws Street value
• Neutral Sentiment: The sharp move was amplified by a short squeeze. Reports estimate that short sellers faced billions of dollars in mark-to-market losses after the trial news, forcing some to buy shares to cover positions. This technical support can intensify gains but may not represent sustained fundamental demand. Moderna short-sellers report
• Negative Sentiment: Profit-taking and valuation concerns are driving the pullback. The stock’s earlier surge priced in substantial success, and several analysts’ revised targets remained below the prevailing market price. Morgan Stanley raised its target but maintained an equal-weight rating, citing limited near-term upside. Moderna valuation concerns
• Negative Sentiment: Important risks remain. Moderna has released topline results, but investors are awaiting detailed data, regulatory review and eventual commercialization. Doctors and analysts have also cautioned that enthusiasm may be running ahead of the evidence, leaving the shares vulnerable to further volatility. Moderna personalized mRNA shot analysis

Moderna Price Performance

Moderna stock opened at $133.32 on Friday. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $176.66. The firm has a market capitalization of $53.23 billion, a price-to-earnings ratio of -16.69 and a beta of 0.91. The company has a fifty day simple moving average of $66.58 and a 200-day simple moving average of $55.47. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings results on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. The firm had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company’s revenue for the quarter was up 2.1% on a year-over-year basis. During the same period last year, the firm posted ($2.13) earnings per share. On average, equities analysts anticipate that Moderna, Inc. will post -6.18 EPS for the current fiscal year.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.